Pelthos Therapeutics Inc. (PTHS): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

$12.81M

Year ended 2025-12-31

$34.03M

Trailing 12 months to 2026-06-30

Period ended	Gross Profit	Change YoY	Source filing
2025-12-31	$12.81M	n/a	2026-03-19, From 2025-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Gross Profit	Change YoY
Pelthos Therapeutics Inc. (PTHS)	2025-12-31	$12.81M	n/a
Alpha Cognition Inc. (ACOG)	2025-12-31	$9.62M	n/a
Scilex Holding Co (SCLX)	2025-12-31	$19.65M	-50.7%
X4 Pharmaceuticals, Inc (XFOR)	2025-12-31	$29.36M	n/m
Kymera Therapeutics, Inc. (KYMR)	2025-12-31	$0	n/a
Protalix BioTherapeutics, Inc. (PLX)	2025-12-31	$25.75M	-11.4%
Zeo ScientifiX, Inc. (ZEOX)	2025-10-31	$4.27M	+13.0%
Champions Oncology, Inc. (CSBR)	2026-04-30	$28.52M	-0.1%
Compugen Ltd (CGEN)	2025-12-31	$63.51M	+218.6%

Compare PTHS, ACOG, SCLX, XFOR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗